{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T14:54:53Z","timestamp":1770562493283,"version":"3.49.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,2,19]],"date-time":"2021-02-19T00:00:00Z","timestamp":1613692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000361","name":"Diabetes UK","doi-asserted-by":"publisher","award":["17\/0005627"],"award-info":[{"award-number":["17\/0005627"]}],"id":[{"id":"10.13039\/501100000361","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Diabetologia"],"published-print":{"date-parts":[[2021,6]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Aims\/hypothesis<\/jats:title>\n                <jats:p>The aim of this work was to map the number of prescribed drugs over age, sex and area-based socioeconomic deprivation, and to examine the association between the number of drugs and particular high-risk drug classes with adverse health outcomes among a national cohort of individuals with type 1 diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Utilising linked healthcare records from the population-based diabetes register of Scotland, we identified 28,245 individuals with a diagnosis of type 1 diabetes on 1 January 2017. For this population, we obtained information on health status, predominantly reflecting diabetes-related complications, and information on the total number of drugs and particular high-risk drug classes prescribed. We then studied the association of these baseline-level features with hospital admissions for falls, diabetic ketoacidosis (DKA), and hypoglycaemia or death within the subsequent year using multivariate Cox proportional hazards models.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Not considering insulin and treatment for hypoglycaemia, the mean number of prescribed drugs was 4.00 (SD 4.35). The proportion of individuals being prescribed five or more drugs at baseline consistently increased with age (proportion [95% CI]: 0\u201319\u00a0years 2.04% [1.60, 2.49]; 40\u201349\u00a0years 28.50% [27.08, 29.93]; 80+ years 76.04% [67.73, 84.84]). Controlling for age, sex, area-based socioeconomic deprivation and health status, each additional drug at baseline was associated with an increase in the hazard for hospitalisation for falls, hypoglycaemia and death but not for DKA admissions (HR [95% CI]: falls 1.03 [1.01, 1.06]; DKA 1.01 [1.00, 1.03]; hypoglycaemia 1.05 [1.02, 1.07]; death 1.04 [1.02, 1.06]). We found a number of drug classes to be associated with an increased hazard of one or more of these adverse health outcomes, including antithrombotic\/anticoagulant agents, corticosteroids, opioids, antiepileptics, antipsychotics, hypnotics and sedatives, and antidepressants.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Polypharmacy is common among the Scottish population with type 1 diabetes and is strongly patterned by sociodemographic factors. The number of prescribed drugs and the prescription of particular high-risk drug classes are strong markers of an increased risk of adverse health outcomes, including acute complications of diabetes.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Graphical abstract<\/jats:title>\n                \n              <\/jats:sec>","DOI":"10.1007\/s00125-021-05394-7","type":"journal-article","created":{"date-parts":[[2021,2,20]],"date-time":"2021-02-20T01:30:13Z","timestamp":1613784613000},"page":"1309-1319","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["The association of polypharmacy and high-risk drug classes with adverse health outcomes in the Scottish population with type 1 diabetes"],"prefix":"10.1007","volume":"64","author":[{"name":"on behalf of the Scottish Diabetes Research Network (SDRN) Epidemiology Group","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7170-1205","authenticated-orcid":false,"given":"Andreas","family":"H\u00f6hn","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8701-0233","authenticated-orcid":false,"given":"Anita","family":"Jeyam","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9009-9179","authenticated-orcid":false,"given":"Thomas M.","family":"Caparrotta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3292-4633","authenticated-orcid":false,"given":"Stuart J.","family":"McGurnaghan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9775-253X","authenticated-orcid":false,"given":"Joseph E.","family":"O\u2019Reilly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4234-8040","authenticated-orcid":false,"given":"Luke A. K.","family":"Blackbourn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3957-1981","authenticated-orcid":false,"given":"Rory J.","family":"McCrimmon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0570-5678","authenticated-orcid":false,"given":"Graham P.","family":"Leese","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8214-7625","authenticated-orcid":false,"given":"John A.","family":"McKnight","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4963-5870","authenticated-orcid":false,"given":"Brian","family":"Kennon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9868-5217","authenticated-orcid":false,"given":"Robert S.","family":"Lindsay","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1604-2593","authenticated-orcid":false,"given":"Naveed","family":"Sattar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7824-2569","authenticated-orcid":false,"given":"Sarah H.","family":"Wild","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5217-1034","authenticated-orcid":false,"given":"Paul M.","family":"McKeigue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8345-3288","authenticated-orcid":false,"given":"Helen M.","family":"Colhoun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,2,19]]},"reference":[{"issue":"15","key":"5394_CR1","doi-asserted-by":"publisher","first-page":"1407","DOI":"10.1056\/NEJMoa1608664","volume":"376","author":"A Rawshani","year":"2017","unstructured":"Rawshani A, Rawshani A, Franz\u00e9n S et al (2017) Mortality and cardiovascular disease in type 1 and type 2 diabetes. N Engl J Med 376(15):1407\u20131418. https:\/\/doi.org\/10.1056\/NEJMoa1608664","journal-title":"N Engl J Med"},{"issue":"1","key":"5394_CR2","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1001\/jama.2014.16425","volume":"313","author":"SJ Livingstone","year":"2015","unstructured":"Livingstone SJ, Levin D, Looker HC et al (2015) Estimated life expectancy in a Scottish cohort with type 1 diabetes, 2008-2010. JAMA 313(1):37\u201344. https:\/\/doi.org\/10.1001\/jama.2014.16425","journal-title":"JAMA"},{"issue":"6","key":"5394_CR3","doi-asserted-by":"publisher","first-page":"1167","DOI":"10.1007\/s00125-016-3914-7","volume":"59","author":"D Petrie","year":"2016","unstructured":"Petrie D, Lung TWC, Rawshani A et al (2016) Recent trends in life expectancy for people with type 1 diabetes in Sweden. Diabetologia 59(6):1167\u20131176. https:\/\/doi.org\/10.1007\/s00125-016-3914-7","journal-title":"Diabetologia"},{"issue":"12","key":"5394_CR4","doi-asserted-by":"publisher","first-page":"3863","DOI":"10.2337\/dc12-2455","volume":"36","author":"MI Constantino","year":"2013","unstructured":"Constantino MI, Molyneaux L, Limacher-Gisler F et al (2013) Long-term complications and mortality in young-onset diabetes. Diabetes Care 36(12):3863\u20133869. https:\/\/doi.org\/10.2337\/dc12-2455","journal-title":"Diabetes Care"},{"issue":"3","key":"5394_CR5","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1007\/s00125-019-05052-z","volume":"63","author":"M Colombo","year":"2020","unstructured":"Colombo M, McGurnaghan SJ, Bell S et al (2020) Predicting renal disease progression in a large contemporary cohort with type 1 diabetes mellitus. Diabetologia 63(3):636\u2013647. https:\/\/doi.org\/10.1007\/s00125-019-05052-z","journal-title":"Diabetologia"},{"key":"5394_CR6","unstructured":"The Academy of Medical Sciences (2018) Multimorbidity - a priority for global health research. Available from https:\/\/acmedsci.ac.uk\/file-download\/82222577. Accessed 7 Jan 2021"},{"issue":"1","key":"5394_CR7","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1186\/s12877-017-0621-2","volume":"17","author":"N Masnoon","year":"2017","unstructured":"Masnoon N, Shakib S, Kalisch-Ellett L, Caughey GE (2017) What is polypharmacy? A systematic review of definitions. BMC Geriatr 17(1):230","journal-title":"BMC Geriatr"},{"issue":"6","key":"5394_CR8","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s00228-014-1668-z","volume":"70","author":"EA Saedder","year":"2014","unstructured":"Saedder EA, Brock B, Nielsen LP, Bonnerup DK, Lisby M (2014) Identifying high-risk medication: A systematic literature review. Eur J Clin Pharmacol 70(6):637\u2013645. https:\/\/doi.org\/10.1007\/s00228-014-1668-z","journal-title":"Eur J Clin Pharmacol"},{"issue":"1","key":"5394_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s12916-015-0322-7","volume":"13","author":"B Guthrie","year":"2015","unstructured":"Guthrie B, Makubate B, Hernandez-Santiago V, Dreischulte T (2015) The rising tide of polypharmacy and drug-drug interactions: Population database analysis 1995\u20132010. BMC Med 13(1):74","journal-title":"BMC Med"},{"key":"5394_CR10","doi-asserted-by":"publisher","first-page":"289","DOI":"10.2147\/CLEP.S153458","volume":"10","author":"L Morin","year":"2018","unstructured":"Morin L, Johnell K, Laroche M-L, Fastbom J, Wastesson JW (2018) The epidemiology of polypharmacy in older adults: Register-based prospective cohort study. Clin Epidemiol 10:289\u2013298","journal-title":"Clin Epidemiol"},{"key":"5394_CR11","doi-asserted-by":"publisher","unstructured":"Marengoni A, Onder G (2015) Guidelines, polypharmacy, and drug-drug interactions in patients with multimorbidity. BMJ Editorial 350:h1059. https:\/\/doi.org\/10.1007\/s40266-015-0324-3","DOI":"10.1007\/s40266-015-0324-3"},{"issue":"4","key":"5394_CR12","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1111\/bcp.12596","volume":"80","author":"E Davies","year":"2015","unstructured":"Davies E, O\u2019Mahony M (2015) Adverse drug reactions in special populations\u2013the elderly. Br J Clin Pharmacol 80(4):796\u2013807. https:\/\/doi.org\/10.1111\/bcp.12596","journal-title":"Br J Clin Pharmacol"},{"key":"5394_CR13","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.ejim.2016.12.003","volume":"38","author":"C Breuker","year":"2017","unstructured":"Breuker C, Abraham O, di Trapanie L et al (2017) Patients with diabetes are at high risk of serious medication errors at hospital: Interest of clinical pharmacist intervention to improve healthcare. Eur J Intern Med 38:38\u201345. https:\/\/doi.org\/10.1016\/j.ejim.2016.12.003","journal-title":"Eur J Intern Med"},{"issue":"12","key":"5394_CR14","doi-asserted-by":"publisher","first-page":"1185","DOI":"10.1080\/14740338.2018.1546841","volume":"17","author":"JW Wastesson","year":"2018","unstructured":"Wastesson JW, Morin L, Tan ECK, Johnell K (2018) An update on the clinical consequences of polypharmacy in older adults: A narrative review. Expert Opin Drug Saf 17(12):1185\u20131196. https:\/\/doi.org\/10.1080\/14740338.2018.1546841","journal-title":"Expert Opin Drug Saf"},{"key":"5394_CR15","unstructured":"Scottish Government Polypharmacy Model of Care Group (2018) Polypharmacy Guidance, Realistic Prescribing 3rd Edition, 2018. Available from https:\/\/www.therapeutics.scot.nhs.uk\/wp-content\/uploads\/2018\/09\/Polypharmacy-Guidance-2018.pdf. Accessed 7 Jan 2021"},{"issue":"8","key":"5394_CR16","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1002\/psb.1779","volume":"30","author":"A Mair","year":"2019","unstructured":"Mair A, Wilson M, Dreischulte T (2019) The polypharmacy programme in Scotland: Realistic prescribing. Prescriber 30(8):10\u201316. https:\/\/doi.org\/10.1002\/psb.1779","journal-title":"Prescriber"},{"issue":"1","key":"5394_CR17","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cger.2014.08.017","volume":"31","author":"EP Peron","year":"2015","unstructured":"Peron EP, Ogbonna KC, Donohoe KL (2015) Antidiabetic medications and polypharmacy. Clin Geriatr Med 31(1):17\u201327. https:\/\/doi.org\/10.1016\/j.cger.2014.08.017","journal-title":"Clin Geriatr Med"},{"issue":"2","key":"5394_CR18","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00592-015-0790-4","volume":"53","author":"M Noale","year":"2016","unstructured":"Noale M, Veronese N, Cavallo Perin P et al (2016) Polypharmacy in elderly patients with type 2 diabetes receiving oral antidiabetic treatment. Acta Diabetol 53(2):323\u2013330. https:\/\/doi.org\/10.1007\/s00592-015-0790-4","journal-title":"Acta Diabetol"},{"issue":"1","key":"5394_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1093\/ageing\/afw174","volume":"46","author":"S Hamada","year":"2017","unstructured":"Hamada S, Gulliford MC (2017) Drug prescribing during the last year of life in very old people with diabetes. Age Ageing 46(1):147\u2013151. https:\/\/doi.org\/10.1093\/ageing\/afw174","journal-title":"Age Ageing"},{"issue":"5","key":"5394_CR20","doi-asserted-by":"publisher","first-page":"e020852","DOI":"10.1136\/bmjopen-2017-020852","volume":"8","author":"M Alwhaibi","year":"2018","unstructured":"Alwhaibi M, Balkhi B, Alhawassi TM et al (2018) Polypharmacy among patients with diabetes: A cross-sectional retrospective study in a tertiary hospital in Saudi Arabia. BMJ Open 8(5):e020852. https:\/\/doi.org\/10.1136\/bmjopen-2017-020852","journal-title":"BMJ Open"},{"issue":"7","key":"5394_CR21","doi-asserted-by":"publisher","first-page":"2034","DOI":"10.2337\/dc14-1140","volume":"37","author":"JL Chiang","year":"2014","unstructured":"Chiang JL, Kirkman MS, Laffel LMB, Peters AL (2014) Type 1 diabetes through the life span: A position statement of the American Diabetes Association. Diabetes Care 37(7):2034\u20132054. https:\/\/doi.org\/10.2337\/dc14-1140","journal-title":"Diabetes Care"},{"issue":"5","key":"5394_CR22","doi-asserted-by":"publisher","first-page":"686","DOI":"10.2337\/dc15-1990","volume":"39","author":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group","year":"2016","unstructured":"Diabetes Control and Complications Trial (DCCT)\/Epidemiology of Diabetes Interventions and Complications (EDIC) Study Research Group (2016) Intensive diabetes treatment and cardiovascular outcomes in type 1 diabetes: The DCCT\/EDIC study 30-year follow-up. Diabetes Care 39(5):686\u2013693. https:\/\/doi.org\/10.2337\/dc15-1990","journal-title":"Diabetes Care"},{"issue":"8","key":"5394_CR23","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00125-019-4900-7","volume":"62","author":"C Mair","year":"2019","unstructured":"Mair C, Wulaningsih W, Jeyam A et al (2019) Glycaemic control trends in people with type 1 diabetes in Scotland 2004\u20132016. Diabetologia 62(8):1375\u20131384. https:\/\/doi.org\/10.1007\/s00125-019-4900-7","journal-title":"Diabetologia"},{"key":"5394_CR24","unstructured":"WHO Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health (2019) ATC\/DDD Index 2021 Available from https:\/\/www.whocc.no\/atc_ddd_index\/. Accessed 7 Jan 2021"},{"issue":"7456","key":"5394_CR25","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/bmj.329.7456.15","volume":"329","author":"M Pirmohamed","year":"2004","unstructured":"Pirmohamed M, James S, Meakin S et al (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18 820 patients. BMJ 329(7456):15\u201319. https:\/\/doi.org\/10.1136\/bmj.329.7456.15","journal-title":"BMJ"},{"issue":"2","key":"5394_CR26","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1111\/j.1365-2125.2006.02698.x","volume":"63","author":"RL Howard","year":"2007","unstructured":"Howard RL, Avery AJ, Slavenburg S et al (2007) Which drugs cause preventable admissions to hospital? A systematic review. Br J Clin Pharmacol 63(2):136\u2013147. https:\/\/doi.org\/10.1111\/j.1365-2125.2006.02698.x","journal-title":"Br J Clin Pharmacol"},{"key":"5394_CR27","unstructured":"Scottish Government (2016) The Scottish Index of Multiple Deprivation (SIMD) 2016. Available from https:\/\/www.gov.scot\/publications\/scottish-index-multiple-deprivation-2016\/. Accessed 7 Jan 2021"},{"issue":"12","key":"5394_CR28","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1111\/j.1463-1326.2012.01636.x","volume":"14","author":"M Peyrot","year":"2012","unstructured":"Peyrot M, Barnett A, Meneghini L, Schumm-Draeger P-M (2012) Factors associated with injection omission\/non-adherence in the global attitudes of patients and physicians in insulin therapy study. Diabetes Obes Metab 14(12):1081\u20131087. https:\/\/doi.org\/10.1111\/j.1463-1326.2012.01636.x","journal-title":"Diabetes Obes Metab"},{"key":"5394_CR29","doi-asserted-by":"publisher","unstructured":"Eilers PHC, Marx BD (1996) Flexible smoothing with B-splines and penalties. Statist Sci 11(2):89\u2013121. https:\/\/doi.org\/10.1214\/ss\/1038425655","DOI":"10.1214\/ss\/1038425655"},{"issue":"5","key":"5394_CR30","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00228-013-1639-9","volume":"70","author":"RA Payne","year":"2014","unstructured":"Payne RA, Avery AJ, Duerden M, Saunders CL, Simpson CR, Abel GA (2014) Prevalence of polypharmacy in a Scottish primary care population. Eur J Clin Pharmacol 70(5):575\u2013581. https:\/\/doi.org\/10.1007\/s00228-013-1639-9","journal-title":"Eur J Clin Pharmacol"},{"key":"5394_CR31","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/j.socscimed.2019.03.002","volume":"228","author":"A Oksuzyan","year":"2019","unstructured":"Oksuzyan A, Da\u0144ko MJ, Caputo J, Jasilionis D, Shkolnikov VM (2019) Is the story about sensitive women and stoical men true? Gender differences in health after adjustment for reporting behavior. Soc Sci Med 228:41\u201350. https:\/\/doi.org\/10.1016\/j.socscimed.2019.03.002","journal-title":"Soc Sci Med"},{"issue":"1","key":"5394_CR32","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1186\/1475-9276-12-67","volume":"12","author":"KD Lawson","year":"2013","unstructured":"Lawson KD, Mercer SW, Wyke S et al (2013) Double trouble: The impact of multimorbidity and deprivation on preference-weighted health related quality of life a cross sectional analysis of the Scottish Health Survey. Int J Equity Health 12(1):67. https:\/\/doi.org\/10.1186\/1475-9276-12-67","journal-title":"Int J Equity Health"},{"issue":"2","key":"5394_CR33","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s40264-015-0378-5","volume":"39","author":"CA Cadogan","year":"2016","unstructured":"Cadogan CA, Ryan C, Hughes CM (2016) Appropriate polypharmacy and medicine safety: When many is not too many. Drug Saf 39(2):109\u2013116. https:\/\/doi.org\/10.1007\/s40264-015-0378-5","journal-title":"Drug Saf"},{"issue":"11","key":"5394_CR34","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1111\/j.1463-1326.2010.01255.x","volume":"12","author":"E Wright Jr","year":"2010","unstructured":"Wright E Jr, Stonehouse A, Cuddihy R (2010) In support of an early polypharmacy approach to the treatment of type 2 diabetes. Diabetes Obes Metab 12(11):929\u2013940. https:\/\/doi.org\/10.1111\/j.1463-1326.2010.01255.x","journal-title":"Diabetes Obes Metab"},{"issue":"2","key":"5394_CR35","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1007\/s11606-009-1179-2","volume":"25","author":"ES Huang","year":"2010","unstructured":"Huang ES, Karter AJ, Danielson KK, Warton EM, Ahmed AT (2010) The association between the number of prescription medications and incident falls in a multi-ethnic population of adult type-2 diabetes patients: The diabetes and aging study. J Gen Intern Med 25(2):141\u2013146. https:\/\/doi.org\/10.1007\/s11606-009-1179-2","journal-title":"J Gen Intern Med"},{"issue":"12","key":"5394_CR36","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1111\/jgs.13153","volume":"62","author":"TR Fried","year":"2014","unstructured":"Fried TR, O\u2019Leary J, Towle V, Goldstein MK, Trentalange M, Martin DK (2014) Health outcomes associated with polypharmacy in community-dwelling older adults: A systematic review. J Am Geriatr Soc 62(12):2261\u20132272. https:\/\/doi.org\/10.1111\/jgs.13153","journal-title":"J Am Geriatr Soc"},{"issue":"6","key":"5394_CR37","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1016\/j.japh.2017.06.002","volume":"57","author":"N Leelakanok","year":"2017","unstructured":"Leelakanok N, Holcombe AL, Lund BC, Gu X, Schweizer ML (2017) Association between polypharmacy and death: A systematic review and meta-analysis. J Am Pharm Assoc 57(6):729\u2013738. https:\/\/doi.org\/10.1016\/j.japh.2017.06.002","journal-title":"J Am Pharm Assoc"},{"issue":"5","key":"5394_CR38","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1093\/gerona\/gly104","volume":"74","author":"A Oksuzyan","year":"2019","unstructured":"Oksuzyan A, Sauer T, Gampe J et al (2019) Is who you ask important? Concordance between survey and registry data on medication use among self- and proxy-respondents in the longitudinal study of aging Danish Twins and the Danish 1905-Cohort Study. J Gerontol Ser A 74(5):742\u2013747. https:\/\/doi.org\/10.1093\/gerona\/gly104","journal-title":"J Gerontol Ser A"},{"issue":"4","key":"5394_CR39","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1016\/j.amjopharm.2007.12.002","volume":"5","author":"ER Hajjar","year":"2007","unstructured":"Hajjar ER, Cafiero AC, Hanlon JT (2007) Polypharmacy in elderly patients. Am J Geriatr Pharmacother 5(4):345\u2013351. https:\/\/doi.org\/10.1016\/j.amjopharm.2007.12.002","journal-title":"Am J Geriatr Pharmacother"},{"key":"5394_CR40","doi-asserted-by":"publisher","unstructured":"Zelko E, Klemenc-Ketis Z, Tusek-Bunc K (2016) Medication adherence in elderly with polypharmacy living at home: A systematic review of existing studies. Mater Sociomed 28(2):129\u2013132. https:\/\/doi.org\/10.5455\/msm.2016.28.129-132","DOI":"10.5455\/msm.2016.28.129-132"},{"key":"5394_CR41","unstructured":"National Institute for Health and Care Excellence (2015) Medicines and prescribing. Medicines optimisation: The safe and effective use of medicines to enable the best possible outcomes. Available from https:\/\/www.nice.org.uk\/guidance\/ng5. Accessed 7 Jan 2021"},{"issue":"680","key":"5394_CR42","doi-asserted-by":"publisher","first-page":"e190","DOI":"10.3399\/bjgp19X701321","volume":"69","author":"P Duncan","year":"2019","unstructured":"Duncan P, Cabral C, McCahon D, Guthrie B, Ridd MJ (2019) Efficiency versus thoroughness in medication review: A qualitative interview study in UK primary care. Br J Gen Pract 69(680):e190\u2013e198. https:\/\/doi.org\/10.3399\/bjgp19X701321","journal-title":"Br J Gen Pract"},{"issue":"1","key":"5394_CR43","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1111\/bcp.12140","volume":"77","author":"E Hatah","year":"2014","unstructured":"Hatah E, Braund R, Tordoff J, Duffull SB (2014) A systematic review and meta-analysis of pharmacist-led fee-for-services medication review. Br J Clin Pharmacol 77(1):102\u2013115. https:\/\/doi.org\/10.1111\/bcp.12140","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"5394_CR44","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1111\/j.1365-2125.2012.04331.x","volume":"74","author":"A Blenkinsopp","year":"2012","unstructured":"Blenkinsopp A, Bond C, Raynor DK (2012) Medication reviews. Br J Clin Pharmacol 74(4):573\u2013580. https:\/\/doi.org\/10.1111\/j.1365-2125.2012.04331.x","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"5394_CR45","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1186\/s12875-016-0577-x","volume":"18","author":"VJB Huiskes","year":"2017","unstructured":"Huiskes VJB, Burger DM, van den Ende CHM, van den Bemt BJF (2017) Effectiveness of medication review: A systematic review and meta-analysis of randomized controlled trials. BMC Fam Pract 18(1):5","journal-title":"BMC Fam Pract"}],"container-title":["Diabetologia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00125-021-05394-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00125-021-05394-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,5]],"date-time":"2021-05-05T07:03:03Z","timestamp":1620198183000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00125-021-05394-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,19]]},"references-count":45,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["5394"],"URL":"https:\/\/doi.org\/10.1007\/s00125-021-05394-7","relation":{},"ISSN":["0012-186X","1432-0428"],"issn-type":[{"value":"0012-186X","type":"print"},{"value":"1432-0428","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,19]]},"assertion":[{"value":"19 August 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}